March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
May 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
1 citations
,
September 2009 in “Regenerative Medicine” Bioaesthetic therapies could improve healthcare if they safely regenerate cells, tissues, or organs to restore normal function.
January 2022 in “Case Reports in Clinical Medicine” Infrared light helped heal acid burns and improved neck movement.
February 2025 in “Canadian Journal of Health Technologies” Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
December 2022 in “Geriatrics” Good communication helps predict successful aging in older Indonesians.
23 citations
,
August 2018 in “Anais Brasileiros De Dermatologia” Both androgenetic alopecia and alopecia areata negatively impact quality of life, with no significant difference between them.
February 2017 in “International Journal of Research in Dermatology” A six-year-old girl unusually had a hair loss condition common in middle-aged women.
July 2022 in “American Journal of Kidney Diseases” Cultural awareness in healthcare improves patient care and relationships.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
1 citations
,
January 2016 in “Journal of Microbial & Biochemical Technology” The Free Androgen Index (FAI) is the best indicator of early hair loss in men before age 30.
December 2022 in “Jurnal Kesehatan Jompa” AAG causes hair loss in many people, with limited treatments like finasteride, minoxidil, light therapy, and hair transplants.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
13 citations
,
January 2018 in “Annals of Dermatology” Alopecia areata and androgenetic alopecia affect quality of life similarly.
1 citations
,
October 2020 in “Current Drug Discovery Technologies” The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.
3 citations
,
January 2023 in “Dermatology Practical & Conceptual” IMA and IMA/albumin levels don't predict alopecia areata severity.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
9 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” New compounds were made that effectively block enzymes related to prostate issues and hair loss.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
5 citations
,
February 2025 in “Pediatric Dermatology” Ritlecitinib was generally well tolerated in children with alopecia areata.
August 2025 in “International Journal of Molecular Sciences” AVT is highly conserved and may have antimicrobial properties.
February 2026 in “Pharmaceuticals” KRDQN effectively predicts adverse drug reactions with high accuracy and clear explanations.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
November 2018 in “Seminars in Cutaneous Medicine and Surgery” The document's conclusion cannot be provided because the document is not accessible or understandable.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Alopecia areata causes hair loss and affects mental health, with new treatments like JAK inhibitors offering hope.
October 2021 in “Journal of Investigative Dermatology” COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.
June 2026 in “Frontiers in Immunology” JAK inhibitors effectively treat inflammatory skin diseases by targeting specific cytokine signals.
December 2025 in “Cureus” Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.